Literature DB >> 8639538

Modulation of DNA topoisomerase I activity by p53.

C Gobert1, L Bracco, F Rossi, M Olivier, J Tazi, F Lavelle, A K Larsen, J F Riou.   

Abstract

The tumor suppressor protein p53 plays a central role in the cellular response to genotoxic lesions and has been shown to be activated by most anticancer agents such as mitomycin C. We here show that mitomycin C treatment of human MCF7 breast adenocarcinoma cells results in increased topoisomerase I activity as measured by relaxation of supercoiled DNA and by phosphorylation of SR protein splicing factor. The increase in catalytic activity occurs in parallel with the nuclear accumulation of p53, resulting in detectable activation of topoisomerase I within less than 1 h of drug treatment. Furthermore, topoisomerase I co-immunoprecipitates with nuclear p53, suggesting that the activation of topoisomerase I may be a result of a direct interaction between the two proteins. In vitro experiments with purified recombinant proteins show that p53 increases the catalytic activities of topoisomerase I as measured by relaxation of supercoiled DNA, stabilization of the covalent topoisomerase I-DNA complex (in the presence of camptothecin), and phosphorylation of SR protein splicing factor ASF/SF2. Furthermore, topoisomerase I sediments at a higher molecular weight in the presence of p53 as revealed by sucrose density gradient analysis in the absence of DNA. Finally, p53 modifies the thermal stability of topoisomerase I, protecting it from heat denaturation. Taken together, our results show that topoisomerase I and p53 form molecular complexes in vitro as in vivo, and we suggest that the p53-mediated response to DNA damage may, at least in part, involve activation of topoisomerase I.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8639538     DOI: 10.1021/bi952327w

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  21 in total

1.  The interaction between p53 and DNA topoisomerase I is regulated differently in cells with wild-type and mutant p53.

Authors:  C Gobert; A Skladanowski; A K Larsen
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

2.  Subnuclear distribution of topoisomerase I is linked to ongoing transcription and p53 status.

Authors:  Yinghui Mao; Issac R Mehl; Mark T Muller
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

3.  p53 stimulates human topoisomerase I activity by modulating its DNA binding.

Authors:  Kent Søe; Frank Grosse
Journal:  Nucleic Acids Res       Date:  2003-11-15       Impact factor: 16.971

4.  Residues 190-210 of human topoisomerase I are required for enzyme activity in vivo but not in vitro.

Authors:  Morten O Christensen; Hans U Barthelmes; Fritz Boege; Christian Mielke
Journal:  Nucleic Acids Res       Date:  2003-12-15       Impact factor: 16.971

5.  Potential protein partners for the N-terminal domain of human topoisomerase I revealed by phage display.

Authors:  Agata M Trzcińska; Agnieszka Girstun; Agnieszka Piekiełko; Barbara Kowalska-Loth; Krzysztof Staroń
Journal:  Mol Biol Rep       Date:  2002-12       Impact factor: 2.316

Review 6.  Human DNA topoisomerase I: relaxation, roles, and damage control.

Authors:  John B Leppard; James J Champoux
Journal:  Chromosoma       Date:  2005-04-14       Impact factor: 4.316

7.  Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma.

Authors:  Maryam B Lustberg; Tanios Bekaii-Saab; Donn Young; Gregory Otterson; William Burak; Abbas Abbas; Barbara McCracken-Bussa; Mark E Lustberg; Miguel A Villalona-Calero
Journal:  J Thorac Oncol       Date:  2010-05       Impact factor: 15.609

8.  Interaction between the N-terminus of human topoisomerase I and SV40 large T antigen.

Authors:  P Haluska; A Saleem; T K Edwards; E H Rubin
Journal:  Nucleic Acids Res       Date:  1998-04-01       Impact factor: 16.971

Review 9.  DNA topoisomerase I in oncology: Dr Jekyll or Mr Hyde?

Authors:  A K Larsen; C Gobert
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

10.  A human functional protein interaction network and its application to cancer data analysis.

Authors:  Guanming Wu; Xin Feng; Lincoln Stein
Journal:  Genome Biol       Date:  2010-05-19       Impact factor: 13.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.